OncoMatch

OncoMatch/Clinical Trials/NCT06765109

Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC

Is NCT06765109 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including Neladalkib (NVL-655) and Alectinib for non-small cell lung cancer.

Phase 3RecruitingNuvalent Inc.NCT06765109Data as of May 2026

Treatment: Neladalkib (NVL-655) · AlectinibMulticenter, randomized, controlled, open-label, Phase 3 study designed to demonstrate that neladalkib (NVL-655) is superior to alectinib in prolonging progression-free survival (PFS) in patients with treatment-naïve, Anaplastic Lymphoma Kinase (ALK) positive, advanced Non-Small Cell Lung Cancer (NSCLC).

Check if I qualify

Extracted eligibility criteria

Cancer type

Non-Small Cell Lung Carcinoma

Non-Hodgkin Lymphoma

Biomarker criteria

Required: ALK rearrangement

Documented Anaplastic Lymphoma Kinase (ALK) rearrangement via testing of tissue or blood

Required: ALK other oncogenic driver alteration

Patient's cancer has a known oncogenic driver alteration other than ALK.

Prior therapy

No prior treatment (treatment-naive required)
Max 0 prior lines

Cannot have received: ALK inhibitor (alectinib)

prior ALK tyrosine kinase inhibitor [TKI] such as alectinib is not allowed in any setting

Cannot have received: systemic anticancer treatment

Exception: adjuvant/neoadjuvant chemotherapy allowed if 12 months prior to randomization

No prior systemic anticancer treatment for NSCLC (adjuvant/neoadjuvant chemotherapy allowed if 12 months prior to randomization)

Lab requirements

Cardiac function

QTcF > 470 msec on repeated assessments; clinically significant cardiovascular disease

QT corrected for heart rate by Fridericia's formula (QTcF) > 470 msec on repeated assessments; Clinically significant cardiovascular disease

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • Palo Verde Hematology Oncology · Glendale, Arizona
  • Hoag Hospital Newport Beach · Newport Beach, California
  • University of California, Irvine Health · Orange, California
  • Rocky Mountain Cancer Centers · Boulder, Colorado
  • Sylvester Comprehensive Cancer Center Miami · Miami, Florida

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify